Purpose: HER2 may be a relevant biomarker in Barrett's cancer. We compared three HER2 laboratory methods, standard fluorescence in situ hybridization (FISH), image-based threedimensional FISH in thick (16 Am) sections, and immunohistochemistry, to predict patient outcome. Experimental Design: Tissue microarray sections from 124 Barrett's cancer patients were analyzed by standard FISH on thin (4 Am) sections and by image-based three-dimensional FISH on thick (16 Am) sections for HER2 and chromosome-17, as well for p185HER2 by immunohistochemistry. Correlations with clinical and follow-up data were examined. Results: Only three-dimensional FISH on thick (16 Am) sections revealed HER2 gene copy gain to be associated with increased disease-specific mortality (relative risk, 2.1; 95% confidence interval, 1.06-4.26; P = 0.033). In contrast, standard FISH on thin (4 Am) sections and immunohistochemistry failed to predict clinical outcome. Low-level gain of HER2 occurred frequently in Barrett's cancer (z2.5-4.0 HER2 copies, 59.7%; HER2-to-chromosome-17 ratio, z1.1-2.0; 61.2%) and defined a subpopulation for patient outcome as unfavorable as HER2 gene amplification [disease-free survival, P = 0.017 (HER2 copies)]. This low-level group was neither definable by standard FISH nor immunohistochemistry. No prognostic significance was found for chromosome-17 aneusomy. Conclusions: Low-level copy gains of HER2 define a biologically distinct subpopulation of Barrett's cancer patients. Importantly, these subtle copy number changes are not reliably detected by standard FISH in thin (4 Am) tissue sections, highlighting a thus far unrecognized weakness in HER2 FISH testing. These results should be taken into account for accurate evaluation of biomarkers by FISH and for HER2 FISH testing in tissue sections.Significant strides continue to be made in the treatment of patients with Barrett's cancer (Barrett's esophagus -associated adenocarcinoma), which is now the most common esophageal cancer and which incidence is increasing faster than that of any other malignancy in the United States (1 -3). At this time, early detection and complete surgical resection are the surest ways to cure esophageal cancer (3). Thus, new therapeutic targets and better prognostic markers for patient stratification are needed.Accurate determination of the status of HER2 in cancer provides significant insight into patient prognosis and may also inform selection of chemotherapeutic treatments. The effect of analyzing HER2 status by either fluorescence in situ hybridization (FISH) or immunohistochemistry has been investigated and also reviewed in extensive meta-analyses, supporting that FISH provides a more powerful prognostic indicator (4 -7). This prompted us to investigate the genomic basis of HER2 expression and its prognostic implication in a cohort of Barrett's cancer patients. However, similar to immunohistochemistry methods, not all FISH methods are alike. To date, most FISH studies for standard HER2 testing of paraffinembedded tissue have been d...